Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compounds and methods for the treatment of renal disease

a technology for kidney disease and compounds, applied in the field of compound and method for the treatment of renal disease, can solve the problems of unsatisfactory therapies, less desirable therapies, and disruption of normal glomerular filtration, so as to prolong the circulatory half-life of therapeutic proteins, improve the half-life, or the effect of

Inactive Publication Date: 2010-11-04
OPSONA THERAPEUTICS
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The present invention provides a method for reducing the biological activities of TLR2 in a TLR2 expressing cell or tissue implicated in renal inflammation and disease. This is achieved by contacting the cell or tissue with an antagonist of TLR2 activity or expression. The method can be performed on cells or tissues in a subject, such as kidneys, and can be used to treat or prevent kidney disease. The invention is useful for reducing inflammation and damage to kidneys caused by various conditions such as chronic renal failure, acute renal failure, heterologous nephrotoxic nephritis, glomerulonephritis, sclerosis of the glomerulus, systemic lupus erythematosus, diabetic nephropathy, and immune-mediated disease."

Problems solved by technology

Inflammation of the glomerulus compromises glomerular function, this resulting in a narrowing or blocking of the capillaries which results in a disruption to normal glomerular filtration.
Such therapies are however unsatisfactory for a number of reasons.
Further, the burden or long term dialysis, or the risks associated with transplant surgery and organ rejection also make these therapies less desirable.
Nevertheless, there has been no evidence to date to suggest that blocking the Toll-like Receptor 2 pathway would provide a basis for a treatment for immune-mediated kidney disorders.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compounds and methods for the treatment of renal disease
  • Compounds and methods for the treatment of renal disease
  • Compounds and methods for the treatment of renal disease

Examples

Experimental program
Comparison scheme
Effect test

example 1

Effect of Toll-Like Receptor 2 Agonist on Glomerular Inflammation

Methods

[0222]Methods for generating nephrotoxic antibody, blood counts, processing histology, assessment of histology are disclosed in Brown H J, Lock, H R, Sacks S H, Robson MG TLR2 stimulation of intrinsic kidney cells in the induction of immune mediated glomerulonephritis, J Immunol 2006, 177(3):1925-1931, the contents of which are incorporated herein by reference. These methods were followed in the performance of the present example.

Mice

[0223]Age, gender, and weight-matched wild-type C57BL / 6 mice were obtained from Harlan (Harlan UK Limited, Bicester, Oxon, UK). All mice used were 9 to 10 weeks of age at commencement of the experiments. Animal experiments were performed according to United Kingdom Home Office regulations. The genotype of the TLR2-deficient mice was confirmed by PCR.

Induction of Accelerated Nephrotoxic Nephritis

[0224]A mouse glomerular extract was made as described previously in Brown et al., and se...

example 2

Renal Ischemia

[0243]All experiments reported were conducted as stated in the National Institutes of Health Guide For The Care And Use Of Laboratory Animals (Institute of Laboratory Animal Resources, National Academy Press, Washington D.C., 1996) and were approved by a local animal care and use committee, and in accordance with a currently valid license for experiments on vertebrate animals, issued by the French Ministry for Agriculture and Fisheries to Dr Yara Barreira (N° 31-125 dated 8 Jun. 2002, validity=5 years).

[0244]Nine Experimental groups were used as follows:[0245]1) Sham-operated mice sacrificed 1 day after surgery, n=6,[0246]2) PBS-vehicle-treated mice 15 min before ischemia / 1 day reperfusion, n=6,[0247]3) Isotype control antibody 10 mg / kg-treated mice 15 minutes before ischemia / 1 day reperfusion, n=6 (The isotype control antibody is mouse IgG1 isotype control purchased from RnD systems (catalogue number MAB002), this isotype control antibody having binding specificity fo...

example 3

Renal Ischemia Repeat study

[0279]Five experimental groups were used in Step 1 as follows:[0280]1) Sham-operated mice sacrificed 1 day after surgery, n=4,[0281]2) 20 minutes of ischemia / 1 day reperfusion, n=4,[0282]3) 20 minutes of ischemia / 5 day reperfusion, n=4,[0283]4) 25 minutes of ischemia / 1 day reperfusion, n=4,[0284]5) 25 minutes of ischemia / 1 day reperfusion, n=4.

[0285]Nine Experimental groups were used in Step 2:[0286]1) Sham-operated mice sacrificed 1 day after surgery, n=6,[0287]2) PBS-vehicle-treated mice 15 minutes before ischemia / 1 day reperfusion, n=6,[0288]3) Isotype control antibody 10 mg / kg-treated mice 15 minutes before 25 minutes ischemia / 1 day reperfusion, n=6 (The isotype control antibody is mouse IgG1 isotype control purchased from RnD systems (catalogue number MAB002), this isotype control antibody having binding specificity for Keyhole Limpet Hemocyanin (KLH) antigen),[0289]4) OPN301 anti-TLR2 monoclonal antibody 10 mg / kg-treated mice 15 minutes before 25 min...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
dissociation constantaaaaaaaaaa
Kaaaaaaaaaaa
thicknessaaaaaaaaaa
Login to View More

Abstract

The present invention provides compounds and methods for the treatment and prophylaxis of renal disease and inflammation. In particular the invention provides methods for the treatment of kidney disease and failure through the administration of compounds which function as inhibitors of TLR2 function and expression.

Description

FIELD OF THE INVENTION[0001]The present invention relates to compositions and methods for the treatment and prophylaxis of renal disease. In particular, there is provided methods for the treatment of conditions such as glomerulonephritis which are characterised by inflammation of the glomeruli of the kidney, said methods comprising the use of compounds which antagonise the function of the receptor Toll-like Receptor 2.Background to the Invention[0002]Each kidney is composed of around one million nephrons. The glomerulus, a component of the nephron, is comprised of a bundle of parallel capillaries, this structure being referred to as the Bowman's capsule. the function of the glomerulus is to filter water and solutes from the blood.[0003]Glomerulonephritis is a disease of the kidney which is characterised by the inflammation of the glomeruli. Inflammation of the glomerulus compromises glomerular function, this resulting in a narrowing or blocking of the capillaries which results in a ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395C12N5/071C12N5/07A61P13/12A61P1/16
CPCA61K38/00A61K2039/505G01N2500/02C07K16/2896A61K45/06C07K14/70596A61P1/16A61P3/10A61P13/12A61P31/04A61P31/14A61P37/02A61P37/06A61P43/00
Inventor HEFFERNAN, MARKO'NEILL, LUKEMCGUIRK, PETERKEOGH, BRIANLOCHER, CHRISTOPHER
Owner OPSONA THERAPEUTICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com